Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases

Reuters2026/08/11 11:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Shattuck Labs outlined a strategy to develop potentially first-in-class DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325.
RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn’s disease is expected to start in Q3 2026; 12-week induction data targeted for 1H 2028.
Cash and equivalents and short-term investments totaled USD 208.3 million as of June 30, 2026; runway expected into 2029.
Phase 1 program in healthy participants completed; SL-325 reported 3.7% anti-drug antibody rate; estimated half-life 16 days.
Preclinical pipeline includes SL-846, a DR3 x IL-23 receptor antibody with Phase 1 initiation expected in 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases

You may also like

Crypto prices